Advertisement
Research Article| Volume 14, ISSUE 4, P321-325, May 2008

Download started.

Ok

Folate and vitamin B12 levels in levodopa-treated Parkinson's disease patients: Their relationship to clinical manifestations, mood and cognition

      Abstract

      We tested the hypothesis that mood, clinical manifestations and cognitive impairment of levodopa-treated Parkinson's disease (PD) patients are associated with vitamin B12 and folate deficiency. To this end, we performed this cross-sectional study by measuring serum folate and vitamin B12 blood levels in 111 consecutive PD patients. Levodopa-treated PD patients showed significantly lower serum levels of folate and vitamin B12 than neurological controls, while depressed patients had significantly lower serum folate levels as compared to non-depressed.
      Cognitively impaired PD patients exhibited significantly lower serum vitamin B12 levels as compared to cognitively non-impaired. In conclusion, lower folate levels were associated with depression, while lower vitamin B12 levels were associated with cognitive impairment. The effects of vitamin supplementation merit further attention and investigation.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Parkinsonism & Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Weιntraub D.
        • Moberg P.J.
        • Duda J.E.
        • Katz I.R.
        • Stern M.B.
        Effect of psychiatric and other non-motor symptoms on disability in Parkinson's disease.
        J Am Geriatric Soc. 2004; 52: 784-788
        • Thanvi B.R.
        • Munshi S.K.
        • Vijaykumar N.
        • Lo T.C.N.
        Neuropsychiatric non-motor aspects of Parkinson's disease.
        Postgrad Med J. 2003; 79: 561-565
        • Mathias J.L.
        Neurobehavioral functioning of persons with Parkinson's disease.
        Appl Neuropsychol. 2003; 10: 57-68
        • Nuti A.
        • Ceravolo R.
        • Piccinni A.
        • Dell’ Angelo G.
        • Bellini G.
        • Combaccini G.
        • et al.
        Psychiatric comorbidity in a population of Parkinson's disease patients.
        Eur J Neurol. 2004; 11: 315-320
        • Slaughter J.R.
        • Slaughter K.A.
        • Nichols D.
        • Holmes S.E.
        • Martens R.P.
        Prevalence, clinical manifestations, etiology and treatment of depression in Parkinson's disease.
        J Neuropsychiatry Clin Neurosci. 2001; 13: 187-196
        • Fleminger S.
        Left-sided Parkinson's disease is associated with greater anxiety and depression.
        Psychol Med. 1991; 21: 629-638
        • Merschdorf U.
        • Berg D.
        • Csoti I.
        • Fornadi F.
        • Merz B.
        • Naumann M.
        • et al.
        Psychopathological symptoms of depression in Parkinson's disease compared to major depression.
        Psychopathology. 2003; 36: 221-225
        • McDonald W.A.
        • Richard I.H.
        • DeLong M.R.
        Prevalence, etiology and treatment of depression in Parkinson's disease.
        Biol Psychiatry. 2003; 54: 363-375
        • Starkstein S.E.
        • Preziosi T.J.
        • Bolduc P.L.
        • Robinson R.G.
        Depression in Parkinson's disease.
        J Nerv Ment Dis. 1990; 178: 27-31
        • Bjelland I.
        • Tell G.S.
        • Vollset S.E.
        • Refsum H.
        • Ueland P.M.
        Folate, vitamin B12, homocysteine and the MTHFR 677C->T polymorphism in anxiety and depression: the hordaland homocysteine study.
        Arch Gen Psychiatry. 2003; 60: 618-626
        • Tiemeier H.
        • van Tuijil H.R.
        • Hofman A.
        • Meijer J.
        • Kiliaan A.J.
        • Breteler M.M.
        Vitamin B12, folate and homocysteine in depression: the Rotterdam study.
        Am J Psychiatry. 2002; 159: 2099-2101
        • Rogers J.D.
        • Sanchez-Saffon A.
        • Frol A.B.
        • Diaz-Arrastia R.
        Elevated homocysteine levels in patients treated with levodopa: association with vascular disease.
        Arch Neurol. 2003; 60: 59-64
        • Miller J.W.
        • Selhub J.
        • Nadeau M.R.
        • Thomas C.A.
        • Feldman R.G.
        • Wolf P.A.
        Effect of l-dopa on plasma homocysteine in PD patients on relationship to B-vitamin status.
        Neurology. 2003; 60: 1125-1129
        • Blandini F.
        • Fancellu R.
        • Martignoni E.
        • Mangiagalli A.
        • Pacchetti C.
        • Samuele A.
        • et al.
        Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease.
        Clin Chem. 2001; 47: 1102-1104
        • Yasui K.
        • Kowa H.
        • Nakaso K.
        • Takeshima T.
        • Nakashima K.
        Plasma homocysteine and MTHFR C677T genotype in levodopa treated patients with PD.
        Neurology. 2000; 55: 437-440
        • O’Suilleabhain P.E.
        • Sung V.
        • Hernandez C.
        • Lacritz L.
        • Dewey Jr., R.B.
        • Bottiglieri T.
        • et al.
        Elevated plasma homocysteine levels in patients with Parkinson disease. Motor, affective and cognitive associations.
        Arch Neurol. 2004; 61: 865-868
        • Hoehn M.M.
        • Yahr D.M.
        Parkinsonism: onset, progression and mortality.
        Neurology. 1967; 17: 427-442
        • Folstein M.
        • Folstein S.E.
        • McHugh P.R.
        Mini mental state: a practical method for grading the cognitive state of patients for the clinician.
        J Psychiatr Res. 1975; 12: 189-198
        • Lamberti P.
        • Zoccolela S.
        • Iliceto G.
        • Armenise E.
        • Fraddosio A.
        • de Mari M.
        • et al.
        Effects of levodopa and COMT inhibitors on plasma homocysteine Parkinson's disease patients.
        Mov Disord. 2005; 20: 69-72
        • Zoccolela S.
        • Lamberti P.
        • Armenise E.
        • de Mari M.
        • Lamberti S.V.
        • Mastronardi R.
        • et al.
        Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
        Parkinsonism Relat Disord. 2005; 11: 131-133
        • O’ Suilleabhain P.E.
        • Bottigleri T.
        • Dewey Jr., R.B.
        • Sharma S.
        • Diaz-Arrastia R.
        Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease.
        Mov Disord. 2004; 19: 1403-1408
        • Carney M.W.
        • Chary T.K.
        • Laundy M.
        • et al.
        Red cell folate concentrations in psychiatric patients.
        J Affect Disord. 1990; 19: 207-213
        • Ortega R.M.
        • Manas L.R.
        • Andres P.
        • Gaspar M.J.
        • Agudo F.R.
        • Jimenez A.
        • et al.
        Functional and psychic deterioration in eld]erly people may be aggravated by folate deficiency.
        J Nutr. 1996; 126: 1992-1999
        • Quadri P.
        • Fragiacomo C.
        • Pezzati R.
        • Zanda E.
        • Forloni G.
        • Tettamanti M.
        • et al.
        Homocysteine, folate and vitamin B12 in mild cognitive impairment, Alzheimer disease and vascular dementia.
        Am J Clin Nutr. 2004; 80: 114-122
        • Duan W.
        • Ladenheim B.
        • Cutler R.G.
        • Kruman I.I.
        • Cadet J.L.
        • Mattson M.P.
        Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease.
        J Neurochem. 2002; 80: 101-110
        • Miller J.W.
        Homocysteine, folate deficiency and Parkinson's disease.
        Nutr Rev. 2002; 60: 410-413
        • Giles W.H.
        • Kittner S.J.
        • Anda R.F.
        • Croft J.B.
        • Casper M.L.
        Serum folate and risk for ischemic stroke. First national health and nutrition examination survey epidemiologic follow-up study.
        Stroke. 1995; 26: 1160-1170
        • Allain P.
        • Le Bouil A.
        • Cordillet E.
        • Le Quay L.
        • Bagheri H.
        • Montastruc J.L.
        Sulphate and cysteine levels in the plasma of patients with Parkinson's disease.
        Neurotoxicology. 1995; 16: 527-529
        • Kuhn W.
        • Roebroek R.
        • Blom H.
        • van Oppenraaij D.
        • Pzuntek H.
        • Kretschmer A.
        • et al.
        Elevated plasma levels of homocysteine in Parkinson's disease.
        Eur Neurol. 1998; 40: 225-227
        • Kuhn W.
        • Roebroek R.
        • Blom H.
        • van Oppenraaij D.
        • Muller T.
        Hyperhomocysteinaemia in Parkinson's disease.
        J Neurol. 1998; 245: 811-812